Alligator Bioscience to present new pre-clinical data for ADC-1013 and ATOR-1015 at PEGS conference in Boston, May 4
Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX) announced today that it will present new pre-clinical data on the CD40 agonistic immuno-oncology antibody ADC-1013, and on the bispecific OX40 and CTLA-4 dual targeting antibody ATOR-1015, at the PEGS Third Annual Agonist Immunotherapy Targets conference in Boston. Dr Peter Ellmark, Principal Scientist at Alligator, will give an oral presentation with the title “Tumor-Directed Immunotherapy – Tumor-Localized Immune Activation Using TNFR-SF Agonistic Antibodies” in the evening on May 4 Swedish time.Alligator’s lead programme,